Epicrispr Biotechnologies vs Moderna
Epicrispr Biotechnologies vs Moderna, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Epicrispr Biotechnologies is on 62/100 and Moderna on 77/100.
Where each one leads
Epicrispr Biotechnologies
Leads on none of the measures we hold for both companies.
Moderna
- our overall score: 77/100 against 62/100
- agent readiness: 49/100 against 39/100
- domain rating: 79/100 against 40/100
- headcount: 6,297 against 51
- funding raised: $4.5B against $90.0M
- LinkedIn following: 780,086 against 7,025
At a glance
| Measure | Epicrispr Biotechnologies | Moderna |
|---|---|---|
| What it is | Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD). | Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics. |
| Category | Biotechnology, Therapeutics, Rare Diseases, Epigenetics | Biotechnology, mRNA Technology, Vaccines, Pharmaceuticals |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Services |
| Founded | 2020 | 2010 |
| Headquarters | South San Francisco, United States | Cambridge, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | Epicrispr Biotechnologies | Moderna |
|---|---|---|
| Employees | 51 | 6,297 |
| Open roles | Not published | 100 |
| Total funding | $90.0M | $4.5B |
| Latest round | Series C | Funding Round |
| LinkedIn followers | 7,025 | 780,086 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Epicrispr Biotechnologies | Moderna |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 62/100 | 77/100 |
| Traction | 57/100 | 60/100 |
| Team | 40/100 | 70/100 |
| Community | Not published | 13/100 |
| Search visibility | 20/100 | 46/100 |
| Quality | 78/100 | 90/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (39/100) | D (49/100) |
| Domain ratingLink authority, 0-100 | 40/100 | 79/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Epicrispr Biotechnologies | Moderna |
|---|---|---|
| Hosting | Not detected | AWS |
| CDN | Cloudflare | CloudFront |
| CMS | WordPress | Not detected |
| Frameworks | Jquery, Tailwind CSS, Bootstrap | Next.js |
| Analytics | Google Analytics 4 | Not detected |
What users say
| Measure | Epicrispr Biotechnologies | Moderna |
|---|---|---|
| Community ratingVisitor votes on StartupHub | Not published | 2.0/5 from 1 vote |
Epicrispr Biotechnologies vs Moderna: common questions
Which is better, Epicrispr Biotechnologies or Moderna?
On our 0-100 score Moderna rates higher (77/100 against 62/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.
How do Epicrispr Biotechnologies and Moderna compare on the numbers?
Moderna leads on our overall score (77/100 against 62/100), agent readiness (49/100 against 39/100), domain rating (79/100 against 40/100), headcount (6,297 against 51), funding raised ($4.5B against $90.0M), LinkedIn following (780,086 against 7,025).
Read the full Epicrispr Biotechnologies review and pricing or the Moderna review and pricing. You can also browse other Epicrispr Biotechnologies alternatives we track.

